EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

New Biomarkers for Renal Transporter‐Mediated Drug–Drug Interactions: Metabolomic Effects of Cimetidine, Probenecid, Verapamil, and Rifampin in Humans

Arne Gessner iD, Jörg König iD, Pia Wenisch iD, Markus R Heinrich iD, Peter Stopfer iD, Martin F Fromm iD, Fabian Müller iD

Clinical Pharmacology & Therapeutics · 2025

DOI: 10.1002/cpt.3414 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Pharmacology & Therapeutics, 2025. Verfasst von Arne Gessner und 6 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Experimental and Clinical Pharmacology and Toxicology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany. Hauptthemen laut MEDLINE: Probenecid, Cimetidine, Rifampin, Drug Interactions. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The inhibition of renal transport proteins organic cation transporter 2 (OCT2), multidrug and toxin extrusion proteins (MATE1, MATE2‐K), and organic anion transporters (OAT1, OAT3) causes clinically relevant drug–drug interactions (DDI). Endogenous biomarkers could be used to improve risk prediction of such renal DDIs. While a number of biomarkers for renal DDIs have been described so far, multiple criteria for valid biomarkers have frequently not been investigated, for example, specificity, metabolism, or food effects. Therefore, there is a need for novel biomarkers of renal DDIs. Here, we investigated the global metabolomic effects following the administration of two classical inhibitors of renal transport proteins [cimetidine (OCT2/MATEs), probenecid (OATs)] in human plasma and urine of healthy volunteers. Additionally, we investigated metabolomic effects of two inhibitors of other transporters [verapamil (P‐glycoprotein), rifampin (organic anion transporting polypeptides)] as controls. This analysis shows that both cimetidine and probenecid affect compounds involved in caffeine metabolism, carnitines, and sulfates. Hierarchical cluster analysis of the effects of all four inhibitors on endogenous compounds identified multiple promising new sensitive and specific biomarker candidates for OCT2/MATE‐ or OAT‐mediated DDIs. For OCT2/MATEs, 5‐amino valeric acid betaine (median log 2 ‐fold change of estimated renal elimination: −3.62) presented itself as a promising candidate. For OATs, estimated renal elimination of 7‐methyluric acid and cinnamoylglycine (median log 2 ‐fold changes −3.10 and −1.92, respectively) was both sensitive and specific. This study provides comprehensive information on metabolomic effects of transport protein inhibition in humans and identifies putative new sensitive and specific biomarkers for renal transporter‐mediated DDIs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProbenecidCimetidineRifampinDrug InteractionsBiomarkersOrganic Cation Transport ProteinsMetabolomicsVerapamilOrganic Cation Transporter 2HumansMaleAdultFemaleKidneyYoung AdultOrganic Anion TransportersOrganic Anion Transporters, Sodium-IndependentOrganic Anion Transport Protein 1

Substanzen

ProbenecidCimetidineRifampinBiomarkersOrganic Cation Transport ProteinsVerapamilSLC47A1 protein, humanOrganic Cation Transporter 2SLC47A2 protein, humanSLC22A2 protein, human

Autor:innen und Institutionen

  • Institute of Experimental and Clinical Pharmacology and Toxicology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
  • FAU NeW - Research Center New Bioactive Compounds, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
  • Department of Chemistry and Pharmacy, Pharmaceutical Chemistry, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
  • Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany.

ORCID-Profile: Arne Gessner, Jörg König, Pia Wenisch, Markus R Heinrich, Peter Stopfer, Martin F Fromm, Fabian Müller

Zitieren

APA

Gessner, A., König, J., Wenisch, P., Heinrich, M. R., Stopfer, P., Fromm, M. F., & Müller, F. (2025). New Biomarkers for Renal Transporter‐Mediated Drug–Drug Interactions: Metabolomic Effects of Cimetidine, Probenecid, Verapamil, and Rifampin in Humans. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.3414

Vancouver

Gessner A, König J, Wenisch P, Heinrich MR, Stopfer P, Fromm MF, et al. New Biomarkers for Renal Transporter‐Mediated Drug–Drug Interactions: Metabolomic Effects of Cimetidine, Probenecid, Verapamil, and Rifampin in Humans. Clinical Pharmacology & Therapeutics. 2025. doi:10.1002/cpt.3414

BibTeX
@article{Gessner2025,
  author = {Gessner, Arne and König, Jörg and Wenisch, Pia and Heinrich, Markus R and Stopfer, Peter and Fromm, Martin F and Müller, Fabian},
  title = {New Biomarkers for Renal Transporter‐Mediated Drug–Drug Interactions: Metabolomic Effects of Cimetidine, Probenecid, Verapamil, and Rifampin in Humans},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2025},
  doi = {10.1002/cpt.3414}
}
Kostenlos starten →